NCT03438396 2023-07-25A Trial of Tisotumab Vedotin in Cervical CancerSeagen Inc.Phase 2 Completed102 enrolled 20 charts 1 FDA
NCT03245736 2021-11-04Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.Seagen Inc.Phase 2 Completed5 enrolled 8 charts